IRON DISC MEDICINE INC

Disc Medicine to Participate in Upcoming Investor Conferences

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at three upcoming investor conferences:

  • Guggenheim Second Annual Healthcare Innovation Conference on Monday, November 10th at 4:30 p.m. ET.

  • Stifel 2025 Healthcare Conference on Thursday, November 13th at 8:40 a.m. ET.

  • Jefferies London Healthcare Conference on Wednesday, November 19th at 2:00 p.m. GMT.

Live webcasts of the fireside chats will be available through the investor relations section of the Company's website at and an archived replay will be available after each event.

About Disc Medicine

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit .

Media Contact

Peg Rusconi

Deerfield Group

Investor Relations Contact

Christina Tartaglia

Precision AQ



EN
31/10/2025

Underlying

IRONDISC MEDICINE INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DISC MEDICINE INC

 PRESS RELEASE
Free
IRON DISC MEDICINE I...

Disc Medicine Announces Presentation of Initial Data from RALLY-MF Pha...

Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced two poster presentations, including initial data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of MF, at the ...

4h / 48m 1 EN
 PRESS RELEASE
Free
IRON DISC MEDICINE I...

Disc Medicine to Participate in Upcoming Investor Conferences

Disc Medicine to Participate in Upcoming Investor Conferences WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at three upcoming investor conferences: Guggenheim Second Annual Healthcare Innovation Conference on Monday, November 10th at 4:30 p.m. ET.Stifel 2025 Healthcare Conference on Thursday, No...

October 31, 2025 1 EN
 PRESS RELEASE
Free
IRON DISC MEDICINE I...

Disc Medicine Announces Pricing of $250 Million Upsized Public Offerin...

Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants WATERTOWN, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of the upsized underwritten offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its...

October 21, 2025 1 EN
 PRESS RELEASE
Free
IRON DISC MEDICINE I...

Disc Medicine Announces Proposed Public Offering of Common Stock and P...

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the commencement of an underwritten offering of $220.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common s...

October 20, 2025 1 EN
 PRESS RELEASE
Free
IRON DISC MEDICINE I...

Disc Medicine Provides Update on Hematology Portfolio and Outlines Nea...

Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner’s National Priority Voucher (CNPV), a program designed to shorten the expected NDA review period to 1-2 monthsAcceleration of ongoing efforts to support the potential earlier approval and commercialization of bitopertin for EPP in the US, expected in late 2025 or early 2026Plans to ...

October 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch